Welcome to our dedicated page for Swk Hldgs news (Ticker: SWKH), a resource for investors and traders seeking the latest updates and insights on Swk Hldgs stock.
SWK Holdings Corporation was a life science-focused specialty finance company serving small- and mid-sized commercial-stage healthcare companies. Its recurring news covered operating results, finance receivables, credit-loss allowances, structured debt, royalty monetization, synthetic royalty transactions, asset purchases, and capital returns such as special dividends.
Company updates also addressed material agreements, capital-structure matters, governance developments, and corporate-status changes. SWK later completed a merger with Runway Growth Finance Corp., making its historical news relevant to its specialty finance portfolio, royalty-sale activity, and transition as a public issuer.
SWK Holdings (NASDAQ:SWKH) has provided a comprehensive portfolio update highlighting significant transactions from Q4 2024. The company made several new originations, including a $5.0M advance to Journey Medical, $0.6M to Biotricity (with 600,000 warrants), an $8.0M senior secured loan to Triple Ring Technologies, $2.5M to SKNV, a $25.7M facility expansion with Eton (with 289,736 warrants), and $2.5M to MedMinder.
On the repayments side, SWK received $4.1M from Exeevo's asset sale, $13.0M from Biolase's bankruptcy estate, $1.9M from Trio Healthcare, $4.2M from Veru's FC2 Female Condom sale, and $12.2M final payment from Moleculight. Additional payments are expected in 2025 from various sources, including Exeevo earn-outs and the Biolase estate.
SWK Holdings (SWKH) reported Q3 2024 financial results with GAAP net income of $3.5 million, down from $4.5 million in Q3 2023. Total revenue increased 15.6% to $10.4 million. Net finance receivables grew 14.4% to $255.9 million compared to the previous year. The company's effective yield was 14.6%, up 60 basis points from Q3 2023. Book value per share increased 3.7% to $22.94. The company repurchased approximately 340,000 shares for $5.8 million year-to-date through November 8, 2024. SWK closed new financing deals, including an $11.0 million royalty financing with Relief Therapeutics and a $25.7 million commitment to Eton Pharmaceuticals.
SWK Holdings (NASDAQ:SWKH) reported its Q2 2024 financial results. Key highlights include:
- GAAP net income of $4.4 million, up from $3.9 million in Q2 2023
- Finance receivables segment adjusted non-GAAP net income of $6.5 million, down from $7.6 million in Q2 2023
- Net finance receivables increased 19.0% to $265.5 million
- Effective yield of 14.6%, a 10 bps increase from Q2 2023
- Non-GAAP tangible financing book value per share rose 6.3% to $20.17
The company saw a 21.1% increase in total revenue to $11.5 million. However, it also recorded a $4.1 million provision for credit losses due to impairments on two non-accrual loans. SWK closed an $11 million royalty financing with Relief Therapeutics in August 2024.
SWK Holdings (Nasdaq: SWKH) has appointed Adam C. Rice, CPA, as Chief Financial Officer and promoted Courtney Baker, CPA, to Controller. Rice has over 18 years of experience in finance and accounting, previously serving as CFO of Park Cities Asset Management. His background includes roles in financial operations management, corporate financial planning, and strategic planning. Baker, who joined SWK Holdings in July 2023, has expertise in revenue recognition, SEC reporting, and M&A activity. Both executives are CPAs registered in Texas, strengthening SWK's leadership team in finance and accounting.
SWK Holdings (NASDAQ: SWKH) announced its financial results for Q1 2024. The company reported a GAAP net income of $0.9 million, down from $4.6 million in Q1 2023. Adjusted non-GAAP net income for the finance receivables segment was $2.7 million, compared to $7.3 million in the same quarter last year.
As of March 31, 2024, gross finance receivables were $274.5 million, a 10.3% increase year-over-year, with an effective yield of 14.2%. Despite a $6.0 million impairment to its loan book, the company saw a 23.7% revenue increase in its finance segment to $11.5 million.
The book value per share stood at $22.46, while the non-GAAP tangible financing book value per share was $19.69. During the quarter, SWK repurchased 58,298 shares of common stock for approximately $1 million.
SWK's Enteris division signed an Option and Asset Purchase Agreement and received a low-single-digit million-dollar option fee in April 2024. The company remains focused on high-margin, strategic opportunities in the life sciences finance market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.